Modern biopharmaceuticals : recent success stories /

• Άλλοι συγγραφείς: Knäblein, Jörg
• Μορφή: Ηλ. βιβλίο
• Γλώσσα: English
• Έκδοση: Weinheim : Wiley-VCH Verlag GmbH, 2013.
• Θέματα: Biopharmaceutics.; Electronic books.

Πίνακας περιεχομένων:

• Related Titles; Title Page; Copyright; Dedication; Foreword by Andreas Busch; Foreword by Günter Stock; Preface; Quotes; List of Contributors; Part I: Modern Biopharmaceuticals: Research is the Best Medicine
• Sanitas Summum Bonus; Chapter 1: Twenty Thousand Years of Biotech
• From "Traditional" to "Modern Biotechnology"; 1.1 Biotechnology
• The Science Creating Life; 1.2 The Inauguration of Biotechnology; 1.3 From "Traditional" to "Modern Biotechnology"; 1.4 A Small Molecule from Bacteria
• A Huge Importance for Mankind; 1.5 Biopharmaceuticals
• The Mainstay of Modern Biotechnology
• 1.6 Transformation of the Pharma Industry Through Biotechnology1.7 Biopharmaceutical Production
• Uncorking Bottlenecks or Wasting Surplus Capacity?; 1.8 Conclusion and Outlook; References; Part II: Modern Biopharmaceutical Development Using Stem Cells, Tissues, and Whole Animals; Chapter 2: Induced Pluripotency as Substitute of Somatic Cell Nuclear Transfer?
• The Impact of Induced Pluripotent Stem Cells on Drug Discovery and Regenerative Biopharmaceuticals; 2.1 Introduction; 2.2 Derivation and Growth of hESC; 2.3 Signaling Pathways and Transcription Factors
• 2.4 Differentiation and Applications of hESC2.5 Patient-Specific Nuclear Transfer Stem Cells; 2.6 Patient-Specific Pluripotent Cells Through Direct Reprogramming of Adult Somatic Cells; 2.7 Concluding Remarks and Outlook; Acknowledgment; References; Chapter 3: Pluripotent Stem Cell-Derived Cardiomyocytes for Industrial and Clinical Applications; 3.1 Introduction; 3.2 Pluripotent Stem Cells; 3.3 High-Yield Differentiation of Pluripotent Stem Cells into Cardiomyocytes; 3.4 Purification of Pluripotent Stem Cell-Derived Cardiomyocytes; 3.5 Cardiomyocytes at an Industrial Scale
• 3.6 Utilization of Tissue Engineering Technologies to Advance Cellular Maturity3.7 Concluding Remarks; References; Chapter 4: Industrialization of Functional Mouse Genomics Technologies for Biopharmaceutical Drug Discovery and Development; 4.1 Introduction; 4.2 The Mouse Genetics Story; 4.3 Establishing Inducible Gene Targeting Tools; 4.4 RNAi
• Talking About a Revolution?; 4.5 Further Shortening the Generation Timeline for RNAi Mouse Models; 4.6 Adapting the Mouse Genetics Toolbox for New Applications; References; Part III: Innovative Development Tools for Modern Biopharmaceuticals
• Chapter 5: Standardized Solutions for Quantitative and Real-Time RT-PCR to Accelerate Biopharmaceutical Development5.1 Introduction; 5.2 Potential of Real-Time RT-PCR in Biopharmaceutical Development; 5.3 Accurate Gene Expression Analysis Depends on Standardized Preanalytical Steps; 5.4 Accuracy of Real-Time RT-PCR Depends on Efficient cDNA Synthesis; 5.5 Integration of Preanalytical Steps Streamlines Gene Expression Analysis; 5.6 Overview of Methods for Real-Time RT-PCR; 5.7 Developments in Real-Time PCR Instrumentation; 5.8 The Need for Better Standardization of Quantification Methods